BG104404A - Използване на тиазолидиндиони за лечение на хипергликемия - Google Patents

Използване на тиазолидиндиони за лечение на хипергликемия Download PDF

Info

Publication number: BG104404A
Authority: BG; Bulgaria
Prior art keywords: hyperglycemia; compound; glucose levels; insulin sensitizer; plasma glucose
Prior art date: 1997-10-13

Application number

BG104404A

Other languages

Bulgarian (bg)

English (en)

Inventor

Robin Buckingham

Stephen Smith

Original Assignee

Smithkline Beecham P.L.C.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-10-13

Filing date

2000-05-05

Publication date

2000-12-29

2000-05-05 Application filed by Smithkline Beecham P.L.C. filed Critical Smithkline Beecham P.L.C.

2000-12-29 Publication of BG104404A publication Critical patent/BG104404A/bg

Links

201000001421 hyperglycemia Diseases 0.000 title claims abstract description 44
238000000034 method Methods 0.000 claims abstract description 34
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 26
239000008103 glucose Substances 0.000 claims abstract description 26
231100000252 nontoxic Toxicity 0.000 claims abstract description 5
230000003000 nontoxic effect Effects 0.000 claims abstract description 5
150000001875 compounds Chemical class 0.000 claims description 44
229940122355 Insulin sensitizer Drugs 0.000 claims description 29
239000000203 mixture Substances 0.000 claims description 18
229940123464 Thiazolidinedione Drugs 0.000 claims description 7
HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 claims description 7
238000002360 preparation method Methods 0.000 claims description 7
ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical group O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 claims description 6
150000003839 salts Chemical class 0.000 claims description 6
239000002552 dosage form Substances 0.000 claims description 5
239000012453 solvate Substances 0.000 claims description 5
-1 [(3,4-dihydro-6-hydroxy-2, 5,7,8-tetramethyl-2H-1-benzopyran-2-yl) methoxy] - Chemical class 0.000 claims description 4
239000003814 drug Substances 0.000 claims description 4
238000007410 oral glucose tolerance test Methods 0.000 claims description 4
241000124008 Mammalia Species 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 3
239000008194 pharmaceutical composition Substances 0.000 claims description 3
PDPBIXXIHOWWHA-UHFFFAOYSA-N 2-benzyl-3,4-dihydro-2h-chromene Chemical compound C1CC2=CC=CC=C2OC1CC1=CC=CC=C1 PDPBIXXIHOWWHA-UHFFFAOYSA-N 0.000 claims description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
229960005095 pioglitazone Drugs 0.000 claims description 2
YZFWTZACSRHJQD-UHFFFAOYSA-N ciglitazone Chemical compound C=1C=C(CC2C(NC(=O)S2)=O)C=CC=1OCC1(C)CCCCC1 YZFWTZACSRHJQD-UHFFFAOYSA-N 0.000 claims 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 claims 1
238000012360 testing method Methods 0.000 claims 1
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract description 8
102000004877 Insulin Human genes 0.000 abstract description 4
108090001061 Insulin Proteins 0.000 abstract description 4
229940125396 insulin Drugs 0.000 abstract description 4
230000036470 plasma concentration Effects 0.000 abstract description 3
206010012601 diabetes mellitus Diseases 0.000 description 6
239000003981 vehicle Substances 0.000 description 6
230000002641 glycemic effect Effects 0.000 description 4
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
208000002705 Glucose Intolerance Diseases 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
238000009472 formulation Methods 0.000 description 3
239000007788 liquid Substances 0.000 description 3
238000002156 mixing Methods 0.000 description 3
239000003921 oil Substances 0.000 description 3
235000019198 oils Nutrition 0.000 description 3
201000009104 prediabetes syndrome Diseases 0.000 description 3
230000002265 prevention Effects 0.000 description 3
239000000600 sorbitol Substances 0.000 description 3
235000010356 sorbitol Nutrition 0.000 description 3
239000006188 syrup Substances 0.000 description 3
235000020357 syrup Nutrition 0.000 description 3
239000003826 tablet Substances 0.000 description 3
150000001467 thiazolidinediones Chemical class 0.000 description 3
GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 3
208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
235000010643 Leucaena leucocephala Nutrition 0.000 description 2
240000007472 Leucaena leucocephala Species 0.000 description 2
125000002015 acyclic group Chemical group 0.000 description 2
239000000654 additive Substances 0.000 description 2
239000002775 capsule Substances 0.000 description 2
238000003745 diagnosis Methods 0.000 description 2
229940088679 drug related substance Drugs 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
239000000945 filler Substances 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
229960001641 troglitazone Drugs 0.000 description 2
GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 2
238000009827 uniform distribution Methods 0.000 description 2
239000000080 wetting agent Substances 0.000 description 2
ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
235000019489 Almond oil Nutrition 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
244000060011 Cocos nucifera Species 0.000 description 1
235000013162 Cocos nucifera Nutrition 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
240000006711 Pistacia vera Species 0.000 description 1
YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000008186 active pharmaceutical agent Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000008168 almond oil Substances 0.000 description 1
CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
229940063655 aluminum stearate Drugs 0.000 description 1
230000003444 anaesthetic effect Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000036765 blood level Effects 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
235000019577 caloric intake Nutrition 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
239000004927 clay Substances 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
230000001934 delay Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
235000019441 ethanol Nutrition 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
230000037406 food intake Effects 0.000 description 1
239000000499 gel Substances 0.000 description 1
230000014101 glucose homeostasis Effects 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
239000008187 granular material Substances 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
230000000055 hyoplipidemic effect Effects 0.000 description 1
230000002218 hypoglycaemic effect Effects 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
239000008101 lactose Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
239000008297 liquid dosage form Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
150000002688 maleic acid derivatives Chemical class 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
FJQXCDYVZAHXNS-UHFFFAOYSA-N methadone hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 FJQXCDYVZAHXNS-UHFFFAOYSA-N 0.000 description 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
239000002687 nonaqueous vehicle Substances 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000003182 parenteral nutrition solution Substances 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
229940080313 sodium starch Drugs 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
239000001593 sorbitan monooleate Substances 0.000 description 1
235000011069 sorbitan monooleate Nutrition 0.000 description 1
229940035049 sorbitan monooleate Drugs 0.000 description 1
229940032147 starch Drugs 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008107 starch Substances 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000002278 tabletting lubricant Substances 0.000 description 1
150000003557 thiazoles Chemical class 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
230000002110 toxicologic effect Effects 0.000 description 1
231100000759 toxicological effect Toxicity 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
239000008215 water for injection Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Endocrinology (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Obesity (AREA)
Chemical Kinetics & Catalysis (AREA)
Emergency Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Thiazole And Isothizaole Compounds (AREA)

BG104404A 1997-10-13 2000-05-05 Използване на тиазолидиндиони за лечение на хипергликемия BG104404A (bg)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9721693.1A GB9721693D0 (en)	1997-10-13	1997-10-13	Novel treatment
PCT/GB1998/003064 WO1999018943A1 (fr)	1997-10-13	1998-10-12	Utilisation de thiazolidinediones pour le traitement de l'hyperglycemie

Publications (1)

Publication Number	Publication Date
BG104404A true BG104404A (bg)	2000-12-29

Family

ID=10820482

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG104404A BG104404A (bg)	1997-10-13	2000-05-05	Използване на тиазолидиндиони за лечение на хипергликемия

Country Status (24)

Country	Link
EP (1)	EP1023056A1 (fr)
JP (1)	JP2001519382A (fr)
KR (1)	KR20010024481A (fr)
CN (1)	CN1281359A (fr)
AP (1)	AP2000001787A0 (fr)
AU (1)	AU9547098A (fr)
BG (1)	BG104404A (fr)
BR (1)	BR9815219A (fr)
CA (1)	CA2306086A1 (fr)
CZ (1)	CZ20001297A3 (fr)
EA (1)	EA002659B1 (fr)
GB (1)	GB9721693D0 (fr)
HR (1)	HRP20000255A2 (fr)
HU (1)	HUP0003922A3 (fr)
ID (1)	ID24521A (fr)
IL (1)	IL135513A0 (fr)
NO (1)	NO20001898L (fr)
NZ (1)	NZ503862A (fr)
OA (1)	OA11683A (fr)
PL (1)	PL339813A1 (fr)
SK (1)	SK5312000A3 (fr)
TR (1)	TR200000958T2 (fr)
WO (1)	WO1999018943A1 (fr)
YU (1)	YU28800A (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7045519B2 (en)	1998-06-19	2006-05-16	Chiron Corporation	Inhibitors of glycogen synthase kinase 3

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE186724T1 (de) *	1987-09-04	1999-12-15	Beecham Group Plc	Substituierte thiazolidindionderivate
GB9218830D0 (en) *	1992-09-05	1992-10-21	Smithkline Beecham Plc	Novel compounds
US5457109A (en) *	1993-09-15	1995-10-10	Warner-Lambert Company	Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus

1997
- 1997-10-13 GB GBGB9721693.1A patent/GB9721693D0/en not_active Ceased
1998
- 1998-10-12 SK SK531-2000A patent/SK5312000A3/sk unknown
- 1998-10-12 TR TR2000/00958T patent/TR200000958T2/xx unknown
- 1998-10-12 HU HU0003922A patent/HUP0003922A3/hu unknown
- 1998-10-12 AU AU95470/98A patent/AU9547098A/en not_active Abandoned
- 1998-10-12 ID IDW20000669A patent/ID24521A/id unknown
- 1998-10-12 KR KR1020007003934A patent/KR20010024481A/ko not_active Ceased
- 1998-10-12 EP EP98949086A patent/EP1023056A1/fr not_active Withdrawn
- 1998-10-12 OA OA1200000108A patent/OA11683A/en unknown
- 1998-10-12 PL PL98339813A patent/PL339813A1/xx unknown
- 1998-10-12 YU YU28800A patent/YU28800A/sh unknown
- 1998-10-12 NZ NZ503862A patent/NZ503862A/xx unknown
- 1998-10-12 HR HR20000255A patent/HRP20000255A2/hr not_active Application Discontinuation
- 1998-10-12 JP JP2000515578A patent/JP2001519382A/ja active Pending
- 1998-10-12 EA EA200000419A patent/EA002659B1/ru not_active IP Right Cessation
- 1998-10-12 IL IL13551398A patent/IL135513A0/xx unknown
- 1998-10-12 CN CN98812083A patent/CN1281359A/zh active Pending
- 1998-10-12 CA CA002306086A patent/CA2306086A1/fr not_active Abandoned
- 1998-10-12 AP APAP/P/2000/001787A patent/AP2000001787A0/en unknown
- 1998-10-12 CZ CZ20001297A patent/CZ20001297A3/cs unknown
- 1998-10-12 BR BR9815219-0A patent/BR9815219A/pt not_active Application Discontinuation
- 1998-10-12 WO PCT/GB1998/003064 patent/WO1999018943A1/fr not_active Ceased
2000
- 2000-04-12 NO NO20001898A patent/NO20001898L/no not_active Application Discontinuation
- 2000-05-05 BG BG104404A patent/BG104404A/bg unknown

Also Published As

Publication number	Publication date
NZ503862A (en)	2003-01-31
KR20010024481A (ko)	2001-03-26
SK5312000A3 (en)	2000-09-12
PL339813A1 (en)	2001-01-02
JP2001519382A (ja)	2001-10-23
CZ20001297A3 (cs)	2001-08-15
WO1999018943A1 (fr)	1999-04-22
EP1023056A1 (fr)	2000-08-02
GB9721693D0 (en)	1997-12-10
CA2306086A1 (fr)	1999-04-22
BR9815219A (pt)	2001-01-02
EA200000419A1 (ru)	2000-10-30
CN1281359A (zh)	2001-01-24
EA002659B1 (ru)	2002-08-29
NO20001898D0 (no)	2000-04-12
TR200000958T2 (tr)	2000-08-21
HUP0003922A3 (en)	2001-12-28
OA11683A (en)	2005-01-12
AU9547098A (en)	1999-05-03
HRP20000255A2 (en)	2001-02-28
HUP0003922A2 (hu)	2001-10-28
AP2000001787A0 (en)	2000-06-30
NO20001898L (no)	2000-06-09
IL135513A0 (en)	2001-05-20
YU28800A (sh)	2003-02-28
ID24521A (id)	2000-07-20

Publication	Publication Date	Title
KR100666591B1 (ko)	2007-01-11	티아졸리딘디온 및 메트포르민을 사용한 당뇨병의 치료
KR100671918B1 (ko)	2007-01-22	티아졸리딘디온, 인슐린 분비촉진제 및 디구아니드를사용한 당뇨병의 치료
KR20010013843A (ko)	2001-02-26	로지글리타존 및 인슐린을 사용한 당뇨병의 치료
BG103966A (bg)	2000-07-31	Лечение на диабет с тиазолидиндион и инхибитор наалфа глюкозидазата
KR20010021952A (ko)	2001-03-15	티아졸리딘디온, 인슐린 분비촉진제 및 알파 글루코시다제억제제를 사용한 당뇨병의 치료
KR20080011356A (ko)	2008-02-01	티아졸리딘디온 및 술포닐우레아를 사용한 당뇨병의 치료
UA70302C2 (uk)	2004-10-15	Комбінація тіазолідиндіону і сульфонілсечовини, фармацевтична композиція та спосіб лікування діабету
US20020006939A1 (en)	2002-01-17	Use of thiazolidinediones for the treatment of hyperglycaemia
AP1223A (en)	2003-11-13	Use of thiazolidinediones for the treatment of hyperglycaemia.
US20020082284A1 (en)	2002-06-27	Use of thiazolidinediones for the treatment of hyperglycaemia
KR20010024481A (ko)	2001-03-26	고혈당증 치료용 티아졸리딘디온의 용도
MXPA00003634A (en)	2001-05-07	Use of thiazolidinediones for the treatment of hyperglycaemia
MXPA00003633A (en)	2001-07-31	Use of thiazolidinediones for the treatment of hyperglycaemia
AU4586902A (en)	2002-08-01	Use of thiazolidinediones for the treatment of hyperglycaemia
AU4587002A (en)	2002-08-01	Use of thiazolidinediones for the treatment of hyperglycaemia
CZ2000174A3 (cs)	2000-11-15	Farmaceutický prostředek proti diabetů mellitus a stavům s ním spojeným
MXPA99012098A (en)	2000-08-01	Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitor